ClearPoint Neuro WKN: A2PZ3E ISIN: US18507C1036 Kürzel: CLPT Forum: Aktien Thema: Hauptdiskussion

ClearPoint Neuro GAAP EPS of -$0.15, revenue of $5.1M https://seekingalpha.com/news/3904123-clearpoint-neuro-gaap-eps-of-0_15-revenue-of-5_1m • ClearPoint Neuro press release (NASDAQ:CLPT): Q3 GAAP EPS of -$0.15. Revenue of $5.1M vs $4.6M. • CLPT reaffirmed full year 2022 revenue outlook of between $21.0 and $22.0M. • Cash and short-term investments totaled $40.5M as of Sept 30, 2022. • CLPT said three new products were cleared by FDA in the quarter and are in the process of being deployed in limited market releases before the end of the year. • "We achieved another strong quarter for revenue despite a historically high case cancellation rate and hospital supply chain disruptions." - President and CEO Joe Burnett

https://www.globenewswire.com/news-release/2022/12/12/2571981/0/en/ClearPoint-Neuro-Announces-First-Patient-Enrolled-in-Glioblastoma-Trial-Using-ClearPoint-Prism-Neuro-Laser-Therapy-System-at-Sk%C3%A5ne-University-Hospital-in-Sweden.html

=00=

https://www.globenewswire.com/news-release/2023/01/11/2587014/25687/en/ClearPoint-Neuro-Reports-Fourth-Quarter-and-Full-Year-2022-Preliminary-Revenue-Results-and-Guidance-for-Full-Year-2023-Revenue.html

https://ir.clearpointneuro.com/news-events/press-releases/detail/1082/clearpoint-neuro-reports-fourth-quarter-and-full-year-2022

https://www.globenewswire.com/news-release/2022/09/23/2521573/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-ClearPoint-Prism-Neuro-Laser-Therapy-System.html

https://www.globenewswire.com/news-release/2022/09/19/2518720/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-Software-Version-2-1.html

ClearPoint Neuro Announces FDA Clearance for ClearPoint Maestro™ Brain Model https://www.globenewswire.com/news-release/2022/08/09/2495317/25687/en/ClearPoint-Neuro-Announces-FDA-Clearance-for-ClearPoint-Maestro-Brain-Model.html

ClearPoint Neuro, Inc. Misses Q2 EPS by 16c https://m.investing.com/news/clearpoint-neuro-inc-misses-q2-eps-by-16c-432SI-2868428?ampMode=1

https://www.globenewswire.com/news-release/2022/06/02/2455609/25687/en/ClearPoint-Neuro-Announces-Receipt-of-MDSAP-Certification.html

ClearPoint Neuro Congratulates Partner PTC Therapeutics on Receiving Positive CHMP Opinion for Gene Therapy to Treat AADC Deficiency https://www.globenewswire.com/news-release/2022/05/20/2447753/0/en/ClearPoint-Neuro-Congratulates-Partner-PTC-Therapeutics-on-Receiving-Positive-CHMP-Opinion-for-Gene-Therapy-to-Treat-AADC-Deficiency.html First Gene Therapy Directly Infused into the Brain to be Administered with ClearPoint’s SmartFlow® Cannula

https://www.fool.com/earnings/call-transcripts/2022/05/11/clearpoint-neuro-inc-clpt-q1-2022-earnings-call-tr/

ClearPoint Neuro Reports First Quarter 2022 Results https://www.globenewswire.com/news-release/2022/05/11/2441245/25687/en/ClearPoint-Neuro-Reports-First-Quarter-2022-Results.html

https://www.globenewswire.com/news-release/2022/05/03/2435061/25687/en/ClearPoint-Neuro-and-Higgs-Boson-Health-Announce-Collaboration.html

ClearPoint Neuro Announces FDA Clearance of the SmartFrame Array™ Version 1.1 https://www.globenewswire.com/news-release/2022/04/28/2431949/0/en/ClearPoint-Neuro-Announces-FDA-Clearance-of-the-SmartFrame-Array-Version-1-1.html Next Generation Neuro Navigation System Designed for Use in Both the MRI Suite and Operating Room